Day: February 28, 2024

JACKSONVILLE, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) — Regency Centers, L.P. (“Regency Centers”, the “Company” or “Regency”) announced today that Moody’s Investors Service (“Moody’s”) raised its credit ratings related to the Company to ‘A3’ with a stable outlook. In its public announcement, Moody’s noted “Regency’s consistently strong operating performance such as lease rate and rent per square foot, high-quality and diversified portfolio of grocery-anchored shopping centers, prudent capital strategy, and good liquidity profile.” “We are gratified by the recognition from Moody’s of Regency’s long-standing commitment to operational excellence and balance sheet strength,” said Lisa Palmer, President and Chief Executive Officer. “This tremendous achievement is a testament to our disciplined strategy and the exceptional work of our team...

MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Clinical Showcase webcast from the February 21, 2024 live event is now available in the Events & Presentations section of the Ocugen website. The showcase replay includes more detail on the Phase 3 study design for OCU400, as well as market potential for this first-in-class product candidate. The panel discussion offers first-hand experience from an OCU400 Phase 1/2 clinical trial patient with the RHO mutation who has completed 12 months of therapy and lead investigator, Dr. Byron Lam, Professor of Ophthalmology, Mark J. Daily, Endowed Chair in Ophthalmology at the University of...

SÃO PAULO, Brazil, Feb. 28, 2024 (GLOBE NEWSWIRE) — Lavoro Limited (Nasdaq: LVRO; LVROW), the first U.S.-listed agricultural inputs retailer in Latin America, will issue its financial results for the fiscal second quarter 2024 after market close on Thursday, March 7, 2024. Lavoro management will host a conference call and audio webcast that afternoon at 5:00 p.m. ET (7:00 p.m. BRT) to discuss the results. Conference Call Details Title: Lavoro Fiscal Second Quarter 2024 Earnings Conference Call Event Date: Thursday, March 7, 2024 Time: 5:00 p.m. ET (7:00 p.m. BRT) Participant Numbers: 1-877-407-9716 (U.S.), 1-201-493-6779 (International)Event Link: https://ir.lavoroagro.com/disclosure-and-documents/events/  For interested individuals unable to join the conference call, a dial-in replay of the call will be available through Thursday,...

– Amendment Reduces Bionano’s Outstanding Debt – SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (“Bionano”) (Nasdaq: BNGO) today announced that is has amended the convertible debt financing the company entered into in October 2023 pursuant to which the company agreed to issue and sell to a certain accredited investor (the “Buyer”) (i) in a registered offering by the company (a) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 initially convertible by the Buyer into approximately 15.7 million shares of the company’s common stock (the “Initial Registered Note”), and (b) warrants to purchase up to 21.7 million shares of the company’s common stock, and (ii) in a concurrent private placement, $35.0 million aggregate principal amount of senior secured convertible notes...

PDUFA target action date of August 28, 2024 MAA validated and accepted for review by EMA in December 2023 NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia. The NDA was granted Priority Review status, and the FDA assigned a Prescription Drug User Free Act (PDUFA) target action date of August 28, 2024. The FDA also noted that it is planning to hold an advisory committee meeting to discuss the application. Govorestat was previously granted Pediatric...

MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) — Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company’s geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is projected to reach $4.9 billion by 2032 from $878.9 million in 2022 with an annual growth rate of 18.86%1. GTG’s strategy ensures that the company’s geneType Risk Assessment test portfolio will be able to access this segment of this rapidly growing market in the U.S.2 The initiative is being led by Dr. Malcolm Bohm, who has recently been...

Innovative partnership enables privacy-first identity resolution and audience segmentation for both brands and publishers CHICAGO, Feb. 28, 2024 (GLOBE NEWSWIRE) — Today, TransUnion (NYSE: TRU) announced a partnership between its marketing solutions line, TruAudience®, and Samooha, by Snowflake, a native data clean room solution on Snowflake. The partnership paves the way for a privacy and data-driven future in the advertising industry. This also represents a significant step forward in TransUnion’s pursuit of interoperability everywhere, making its industry-leading consumer data and identity resolution capabilities available across the marketing technology landscape. With this integration, clients can access TransUnion’s marketing identity graph natively within Samooha, by Snowflake’s easy-to-use clean room environment,...

SAN CLEMENTE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) — Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference. Details:Event Oppenheimer 34th Annual Healthcare MedTech & Services ConferenceLocation VirtualDate Wednesday, March 13, 2024Time 3:20 p.m. Eastern Time / 12:20 p.m. Pacific TimeWebcast Click here   About Sofwave MedicalSofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction, lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that its Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in a panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET in Boston, MA. A live webcast of the panel can be accessed by visiting the investor relations section of the Company’s website at: www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event. About Black DiamondBlack Diamond Therapeutics is a clinical-stage oncology company focused on the...

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b725cac9cc6Webcast Registration: http://investors.atyrpharma.com/events-and-webcasts Participants...